Prevention of post-menopausal bone loss with 1α-hydroxy vitamin D3 a three-year prospective study

Pouillès, J. M.; Trémollières, Florence; Ribot, C.

doi:10.1007/bf02283104

Cited by 18 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For a number of treatments, effects appear to persist when treatment is stopped. The evidence of persistence of effect for several years after stopping treatment is greater for hormone replacement therapy [21,22] and the bisphosphonates [23,24] than for calcium, vitamin D or fluorides [25][26][27][28]. Against this background 10 year probabilities are appropriate and were used for this reason in our analysis.…”

Section: Discussionmentioning

confidence: 99%

Ten Year Probabilities of Osteoporotic Fractures According to BMD and Diagnostic Thresholds

Kanis

Johnell

Odén

et al. 2001

Osteoporosis International

720

387

View full text Add to dashboard Cite

The objectives of the present study were to estimate 10 year probabilities of osteoporotic fractures in men and women according to age and bone mineral density (BMD) at the femoral neck. Risks were computed from the incidence of a first hip, distal forearm, proximal humerus and symptomatic vertebral fracture from patient records in Malmö, Sweden and future mortality rates for each year of age from Poisson models using the Swedish patient register and statistical year book. Fracture probability was computed using the Swedish population and cut-off values for T-scores based on the NHANES III female population. We assumed that the risk of fracture increased with decreasing BMD as assessed by meta-analysis in independent studies. The 10-year probability of any fracture was determined from the proportion of individuals fracture-free from the age of 45 years. With the exception of forearm fractures in men, 10 year probabilities increased with age and T-score. In the case of hip and spine fractures, fracture probabilities for any age with low BMD were similar between men and women. The effect of age on risk independently of BMD suggests that intervention thresholds should not be at a fixed T-score but vary according to absolute probabilities. Intervention thresholds based on hip BMD T-scores are similar between sexes.

show abstract

Section: Discussionmentioning

confidence: 99%

Ten Year Probabilities of Osteoporotic Fractures According to BMD and Diagnostic Thresholds

Kanis

Johnell

Odén

et al. 2001

Osteoporosis International

720

387

View full text Add to dashboard Cite

show abstract

“…These were filtered by title and then abstract, in order to exclude irrelevant papers. The initial filtering by title reduced the number of papers to 200. In addition to the abstracts of those papers being reviewed, any non-UK papers plus those published before 1990 were set aside.…”

Section: Methodsmentioning

confidence: 99%

“…The results of one study suggested a catch-up loss over a period of 2-3 years 200 but the results of another prospective randomised study suggested otherwise. 201 In the latter study, patients were followed for a 12-year period.…”

Section: Onset and Offset Of Actionmentioning

confidence: 99%

Treatment of established osteoporosis: a systematic review and cost-utility analysis

Kanis

Brazier

Stevenson

et al. 2002

Health Technol Assess

207

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.Paying by official purchase order You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics and imaging, population screening, methodology) helped to set the research priorities for the HTA Programme. However, during the past few years there have been a number of changes in and around NHS R&D, such as the establishment of the National Institute for Clinical Excellence (NICE) and the creation of three new research programmes: Service Delivery and Organisation (SDO); New and Emerging Applications of Technology (NEAT); and the Methodology Programme.This has meant that the HTA panels can now focus more explicitly on health technologies ('health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care) rather than settings of care. Therefore the panel structure has been redefined and replaced by three new panels: Pharmaceuticals; Therapeutic Procedures (including devices and operations); and Diagnostic Technologies and Screening.The HTA Programme continues to commission both primary and secondary research. The HTA Commissioning Board, supported by the National Coordinating Centre for Health Technology Assessment (NCCHTA), will consider...

show abstract

“…In the study's collective, no severe hypercalcemia was found; the highest measured value under treatment was 2.48 mmol/liter (upper normal value 2.42 mmollliter). This is due to the controlled amount of oral calcium intake which is reported to be 600-800 mg per day [25]. Moreover, a considerable number of our patients have reported an increase in general well-being and a decrease of pain.…”

Section: Discussionmentioning

confidence: 67%

Can the fast bone loss in osteoporotic and osteopenic patients be stopped with active vitamin D metabolites?

Kranich

Schacht³

et al. 1997

Calcif Tissue Int

View full text Add to dashboard Cite

Abstract. The aim of this study was to evaluate whether fast trabecular bone loss in osteoporotic and osteopenic patients can effectively be treated with active vitamin D metabolites. Thirty-one osteoporotic and osteopenic patients were monitored between 4 and 22 months before and between 8 and 18 months during the treatment. Fast bone losers were designated as osteoporotic or osteopenic patients with a loss of trabecular bone density in the radius of 3% or more calculated for 1 year. For this differentiation, the high precise peripheral quantitative computed tomography system (DENSISCAN 1000) was used (reproducability 0.3% in mixed collectives). The pretreatment loss and the "gain" under treatment with active vitamin D metabolites was calculated for 1 year. The treatment consisted of either 0.5 flg calcitriol daily or 1 flg of alfacalcidol daily. Before treatment, the trabecular bone loss in the radius/year was -6.6 ± 0.5% (mean ± SEM). After treatment with vitamin D metabolites, the trabecular bone gain in the radius/year was 0.01 ± 0.6% (mean ± SEM). The difference was highly significant (P < 0.001). In contrast to this, the loss of cortical bone density before treatment was -1.8 ± 0.3% (mean ± SEM) and the reduced loss after treatment -0.2 ± 0.4% (mean ± SEM), both values calculated for I year. This difference was less significant (P < 0.05). This study shows that the treatment with active vitamin D metabolites is very effective in slowing fast trabecular bone loss in osteoporotic and osteopenic patients.Key words: Fast bone loss -Osteoporosis -Quantitative computed tomography -Calcitriol -Alfacalcidol.In postmenopausal and senile osteoporosis, reduced calcium absorption is often reported. Pathophysiologically, a disorder in the vitamin D metabolism as cause can be postulated, although it is of a different character. For both groups a lower concentration of 1,25(OHhD 3 in the serum, a decrease of the amount of 1,25(OHhD3 receptors, and a disorder of the active calcium absorption in the intestine is known. For the postmenopausal osteoporosis there is a low parathyroid hormone (PTH) level and an additional deficit in the activation of the PTH-induced 1,25(OHhD3 synthesis. For the senile osteoporosis, in addition to the above, there is a lack of vitamin D uptake and an increase in the Vitamin D metabolites have proved to be effective in preventing osteoporosis by increasing low mineral density [2] and decreasing fracture rates [3][4][5] while showing a low toxicity; the incidence of hypercalcemia is <1 % [6]. The prevention of bone loss has been shown to be due to restoration to a positive calcium balance due to a correction of calcium malabsorption [7]. Furthermore, it has been reported that treatment with alfacalcidol improves the myopathy associated with the bone loss of aging [8] and should reduce the tendency to fall and the risk of osteoporotic fractures.Until now anabolic substances like fluorides were used for the tailored treatment of osteoporosis in slow bone losers (loss of trabecular bone density in...

show abstract

Prevention of post-menopausal bone loss with 1α-hydroxy vitamin D3 a three-year prospective study

Cited by 18 publications

References 32 publications

Ten Year Probabilities of Osteoporotic Fractures According to BMD and Diagnostic Thresholds

Ten Year Probabilities of Osteoporotic Fractures According to BMD and Diagnostic Thresholds

Treatment of established osteoporosis: a systematic review and cost-utility analysis

Can the fast bone loss in osteoporotic and osteopenic patients be stopped with active vitamin D metabolites?

Contact Info

Product

Resources

About